Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1624 1644 1645
This examiner grants 56% of resolved cases
Bailey Michelle Morgan is in Tech Center 1600 and Art Unit 1624, with 32 resolved cases. The allowance rate is 56.3%, and the median days to allowance is 1220. The interview lift is 58.3%, suggesting that interviews are extremely effective for this examiner.
The 56.3% allowance rate is moderate, but the 58.3% interview lift is a very high figure. This suggests that an interview can significantly increase the chances of success compared to the base rate. For the 32 resolved cases, the 1220-day median pendency is a key factor. Practitioners should prioritize an interview to overcome the hurdles in this docket, as the 58.3% lift indicates that the examiner is very responsive to direct dialogue. This strategy is likely the best way to navigate the 1220-day timeline.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18623087 | CYANOBACTERIAL HOSTS AND METHODS FOR PRODUCING CHEMICALS | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 17796565 | VARIANT OF GENUS YARROWIA AND METHOD OF PREPARING FAT USING THE SAME | Non-Final OA | CJ CHEILJEDANG CORPORATION |
| 18732214 | ANTI-ROXP ANTIBODIES AND USES THEREOF | Non-Final OA | Washington University |
| 18666803 | RHODOPSEUDOMONAS PALUSTRIS TIE-1 STRAINS AND METHODS FOR BIOPLASTIC PRODUCTION | Non-Final OA | WASHINGTON UNIVERSITY |
| 18042231 | COMBINATION IMMUNOTHERAPY METHODS FOR THE TREATMENT OF CANCER | Final Rejection | The Board of Regents of The University of Texas System |
| 18487614 | FLUORESCENCE RESONANCE ENERGY TRANSFER-BASED BIOSENSOR FOR SENSING CHIMERIC ANTIGEN RECEPTOR ACTIVITY AND USE THEREOF | Non-Final OA | SEOUL NATIONAL UNIVERSITY R&db FOUNDATION |
| 18257420 | CONJUGATED T-2 TOXIN TO PROTECT AGAINST MYCOTOXICOSIS | Final Rejection | INTERVET INC. |
| 18271140 | METHODS, ANTIBODIES OR ANTIGEN BINDING FRAGMENTS AND OTHER TOOLS FOR DETERMINING TARGET MOLECULES | Non-Final OA | TEKNOLOGIAN TUTKIMUSKESKUS VTT OY |
| 17763354 | IMMUNOGENIC COMPOSITIONS | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18262949 | VACCINE COMPOSITION FOR BREAKING SELF-TOLERANCE | Non-Final OA | Elanco Animal Health GmbH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy